|
ALOE VERA GEL
is a drinking juice based on the inner gel of the aloe vera leaf.
The plant has anti-inflammatory and immune-boosting properties.
SUITABLE FOR
skin conditions
including eczema and psoriasis, and internal digestive tract-related
problems such as ulcerative colitis,
Crohn’s disease, peptic ulcers and irritable bowel syndrome.
Wonderful comments from one of our customers
In answer to your question, I drink
the juice myself as I have Ulcerative Colitis and have read many
reports on how great it is for this condition. At the time of
purchasing my last order I was experiencing the worst flare up I
have ever had, after six months of maximum medication I was at
the end of my tether!!! I ordered the Gel and within 2 weeks of
drinking it I was back to 'normal' and leading a 'normal' life
once again!!!
Its good stuff. It works!!!
Regards
Lesley
Ulcerative Colitis clinical trial using Aloe Vera
Forever Living Products announces positive results of
UK’s first ever clinical trial using Aloe Vera as a
Forever Living Products (FLP), the
UK’s leading supplier of Aloe Vera products has announced the
results of what is recognized as the first randomised,
placebo-controlled, double blind, clinical trial for ulcerative
colitis ever to be undertaken in the UK, using a herbal approach in
the form of an Aloe Vera drink.
The trial, involved 44 patients who
suffered with the serious inflammatory bowel disease, ulcerative
colitis. The trial was designed to test the effects of Aloe Vera (in
this case Forever Living Product’s Aloe Vera drink) on this
potentially life threatening condition. It was set up as a
randomised, double blind, placebo-controlled trial, i.e. both the
prescribing doctor(s) and the patient(s) are unaware as to whether
they are using the real Aloe Vera
gel or a placebo. The trial, instigated by Dr. David Rampton, a
Professor in the Department of Gastroenterology at the Royal London
Hospital, used volunteers from two major teaching hospitals - The
Royal London Hospital in Lambeth and The John Radcliffe Hospital in
Oxford.
Professor Rampton’s conclusion was:
“Oral
Aloe Vera taken for 4 weeks produces a clinical response more often
than a placebo and it also improves histological disease activity
(the histological disease refers to what is seen under the
microscope when a biopsy is examined) and appears to be safe. These
encouraging results suggest that further evaluation of the
therapeutic potential of Aloe Vera drink in inflammatory bowel
disease is warranted.”
The trial was completed in January
2004 and three different criteria were used to measure the results.
Clinical improvement occurred in an average of 38% of patients given
the active
Aloe Vera Gel,
as opposed to an average of 8 % of patients on the placebo.
Dr. Peter Atherton, a former G.P.
and now the medical consultant on FLP’s Advisory Board, commented on
the news of the trial results. He said,
“I feel this is a ground breaking
piece of research as it is first randomised, placebo
controlled, clinical trial to evaluate a herbal approach to the
treatment of ulcerative colitis. Its importance is signified by the
fact that the trial and the results were presented at the AGM of the
British Society of Gastroenterologists this year.”
“However, the jury has been out for
a long time, as our first ever clinical trial to reach a conclusion
was actually started way back in 1998. I am now delighted to report
at last that there is a positive outcome with this trial.
“I first met Dr. David Rampton, the
instigator of the trial in December 1997. Now a Professor in the
Department of Gastroenterology at the Royal London Hospital, he was
then a Senior Consultant. His interest was initially aroused by the
dramatic effect FLP’s
Aloe Vera
drink had on his daughter’s psoriasis. Apparently, he had witnessed
the stunning results after his daughter started using our products
and the condition had virtually cleared up. As psoriasis is a
disorder of the immune system he postulated that Aloe Vera might
work on other disorders of the immune system such as ulcerative
colitis, in this case an autoimmune disorder where the body attacks
itself.
So here we had a conventional medical
specialist prepared to evaluate an alternative therapy in a way that
would be accepted by the medical fraternity at large. If only all
specialists were so open-minded but at the time this was ground
breaking.
“In those days I was getting
extremely frustrated trying to persuade my medical colleagues to
look at the possibility of any trial and getting absolutely nowhere,
so you can imagine my delight and surprise when, out of the blue,
this doctor rang me up and asked if I would help him set up a trial
- would I?!!”.
Because of the unusual nature of
this trial, the lead researcher Dr. Louise Langmead was invited to
present the findings at the annual meeting of the British Society of
Gastroenterologists in Glasgow on March 23rd 2004 and then at the
American Gastroenterology Association meeting in New Orleans in May
2004. The full paper has been published in the medical journal
“Alimentary Pharmacology and Therapeutics 2004 Apr;19(7):739-47”. It
will be clearly stated that the Aloe Vera drink that was used in the
trial is manufactured by Forever Living Products.
Bob Parker, Managing Director, of Forever Living Products UK, adds,
“We are now eagerly awaiting the
results of an even bigger trial into our
Aloe Vera
drink and irritable bowel syndrome (IBS), currently being conducted
by the Department of Surgery at the Morriston Hospital, Swansea,
Wales. Again, this is the first clinical trial of its kind ever to
be undertaken in the UK.”
FLP is the UK subsidiary of Forever
Living Products Inc., the world’s largest grower, processor,
manufacturer and distributor of Aloe Vera products, with annual
global sales in excess of US$2 billion, operating in over 100
countries.
|
